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ABSTRACT 
Atherosclerosis is a progressive and complex disease, which narrows the lumen of 
arteries and eventually causes cardiovascular complications such as ischaemic heart 
disease and stroke. Hallmarks of the disease development are; a compromised 
endothelial barrier, the accumulation of lipids and immunocompetent monocyte-
derived macrophages (MDM) and T-cells, the formation of MDM foam cells, and 
migration and proliferation of medial arterial smooth muscle cells (SMC) in the 
innermost layer (intima) of the arterial wall. While lipid-lowering therapy favourably 
retards atherosclerosis progression by reducing the lipid component of intimai 
thickenings, there is no effective therapy to control cell accumulation in the intima. A 
key role in this cellular response has been attributed to the Platelet-Derived Growth 
Factor (PDGF). The main aims of this thesis were to establish a better understanding 
of the role of PDGF and its receptors (PDGF-R) in the cellular responses in the 
complex atherosclerotic plaque by studying human SMC and MDM in simplified in 
vitro systems. Specifically, I studied i) if the expressions of PDGF isoforms and their 
receptors are affected by changes in cell phenotype, ii) if this expression is modulated 
by exogenous cytokines, and iii) if different PDGF homodimers affect major cellular 
events in the atherosclerotic lesion; proliferation of SMC and migration of MDM. The 
results showed that human SMC and MDM expressed PDGF and PDGF-Rs in vitro. 
Both PDGF and PDGF-R genes were independently regulated and showed a complex 
gene regulatory pattern. The expression of these genes could be influenced by 
phenotypic changes and cytokines. SMC downregulated PDGF mRNA during 
dedifferentiation upon serum exposure. In contrast, blood-derived monocytes 
differentiated to MDM in the presence of serum and increased both PDGF isoform 
mRNAs, suggesting that PDGF might be important during macrophage differentiation. 
All tested PDGF homodimers (PDGF-AAL, -AAs, and -BBS) induced SMC 
proliferation whereas only PDGF-AAL induced directed migration in early MDM and 
this was coupled to an increase in PDGF-Ra expression. 
Taken together, these results suggest that PDGF-mediated mechanisms may be 
involved in cell accumulation in atherosclerotic lesions, influencing proliferation of 
SMC and chemoattraction of early MDM. 
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ABSTRACT 
Atherosclerosis is a progressive and complex disease, which narrows the lumen of arteries and eventually causes cardiovascular complications 
such as ischaemic heart disease and stroke. Hallmarks of the disease 
development are; a compromised endothelial barrier, the accumulation of lipids 
and immunocompetent monocyte-derived macrophages (MDM) and T-cells, the 
formation of MDM foam cells, and migration and proliferation of medial 
arterial smooth muscle cells (SMC) in the innermost layer (intima) of the 
arterial wall. While lipid-lowering therapy favourably retards atherosclerosis 
progression by reducing the lipid component of intimai thickenings, there is no 
effective therapy to control cell accumulation in the intima. A key role in this 
cellular response has been attributed to the Platelet-Derived Growth Factor 
(PDGF). The main aims of this thesis were to establish a better understanding of 
the role of PDGF and its receptors (PDGF-R) in the cellular responses in the 
complex atherosclerotic plaque by studying human SMC and MDM in 
simplified in vitro systems. Specifically, I studied i) if the expressions of PDGF 
isoforms and their receptors are affected by changes in cell phenotype, ii) if this 
expression is modulated by exogenous cytokines, and iii) if different PDGF 
homodimers affect major cellular events in the atherosclerotic lesion; 
proliferation of SMC and migration of MDM. The results showed that human 
SMC and MDM expressed PDGF and PDGF-Rs in vitro. Both PDGF and 
PDGF-R genes were independently regulated and showed a complex gene 
regulatory pattern. The expression of these genes could be influenced by 
phenotypic changes and cytokines. SMC downregulated PDGF mRNA during 
dedifferentiation upon serum exposure. In contrast, blood-derived monocytes 
differentiated to MDM in the presence of serum and increased both PDGF 
isoform mRNAs, suggesting that PDGF might be important during macrophage 
differentiation. All tested PDGF homodimers (PDGF-AAL, -AAS, and -BBS) 
induced SMC proliferation whereas only PDGF-AAL induced directed 
migration in early MDM and this was coupled to an increase in PDGF-Ra 
expression. 
Taken together, these results suggest that PDGF-mediated mechanisms 
may be involved in cell accumulation in atherosclerotic lesions, influencing 
proliferation of SMC and chemoattraction of early MDM. 
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ABBREVIATIONS 
aFGF Acidic fibroblast growth factor 
Chemokinesis Random motility 
Chemotaxis Directed migration 
Early hMDM Human monocyte-derived macrophage, cultured in SFM 
EC Endothelial cell 
ECM Extracellular matrix 
ELISA Enzyme-linked immunosorbent assay 
GAG Glycosaminoglycan 
hASMC Human arterial smooth muscle cell 
hAVEC Human adult vein endothelial cell 
hMDM Human monocyte-derived macrophage, cultured in SM 
IFN-y Interferon-y 
IL-6 Interleukin-6 
MDM Monocyte-derived macrophage 
PDGF Platelet-derived growth factor 
PDGF-AL Long PDGF-A isoform 
PDGF-As Short PDGF-A isoform 
PDGF-Bl Long PDGF-B isoform 
PDGF-Bs Short PDGF-B isoform 
PDGF-R Platelet-derived growth factor receptor 
PDGF-Ra Platelet-derived growth factor receptor a-subunit 
PDGF-Rß Platelet-derived growth factor receptor ß-subunit 
RT-PCR Reverse-transcriptase polymerase chain reaction 
SFM Serum-free medium 
SM Serum-containing medium 
SMC Smooth muscle cell 
TGF-ß Transforming growth factor-ß 
VSMC Vascular smooth muscle cell 
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INTRODUCTORY REMARKS 
Atherosclerosis is a progressive, complex, and multifactorial disease, which narrows the lumen of arteries and eventually causes cardiovascular 
complications such as ischaemic heart disease and stroke. This narrowing is due 
to patch-wise thickenings of the innermost layer of the arterial wall (intima) by 
the accumulation of lipids (i.e. cholesterol), cells, and extracellular matrix 
(ECM). However, the contribution of each individual component to the 
progression of the disease varies both between plaques and subjects. 
The cholesterol component of the plaque is large in hypercholesterolemia, 
which explains up to 50 % of subsequent fatal and non-fatal myocardial 
infarctions in prospective studies (Pooling Project, 1978; Braunwald, 1997). 
Efficient cholesterol-lowering therapy reduces the incidence of major 
cardiovascular events by about 30 % (Scandinavian Simvastatin Survival Study 
(4S), 1994; Shepherd et al., 1995; Sacks et al., 1996; Fager and Wiklund, 1997). 
Clearly, cholesterol-lowering therapy is efficient in reducing complications of 
atherosclerosis due to hypercholesterolemia but it is unlikely to influence other 
components of atherosclerotic plaques in the large numbers of infarction 
patients with normal cholesterol levels. 
Since hypercholesterolemia only explains approximately 50%" of subsequent 
fatal and non-fatal myocardial infarctions, other factors need to be taken into 
consideration. Up to 50% of the volume of the atherosclerotic wall enlargement 
consists of arterial smooth muscle cell (ASMC) and ASMC-derived ECM. 
There is currently no clinically useful therapy to control intimai cell and ECM 
accumulation. Indeed, our understanding of the mechanisms underlying these 
processes are insufficient even to suggest therapeutic approaches. Therefore, 
more research is needed to provide sound bases for therapeutic developments. 
Current knowledge about the development of atherosclerosis allows us to 
conclude that; 1) the endothelial barrier is compromised in atherosclerosis; 2) 
accumulation of immunocompetent T-cells and monocyte-derived macrophages 
(MDM) and MDM-derived foam cells is an early event in the progression of the 
disease (Ross, 1993); 3) migration and proliferation of medial ASMC often 
contributes to most of the non-lipid plaque volume (Bobik and Campbell, 1993; 
Ross, 1993). 
A compromised endothelium is associated with extravasation of white blood 
cells, platelet adhesion, and loss of the anticoagulant barrier provided by the 
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functional endothelium (Holvoet and Collen, 1997). The loss of an intact 
endothelial surface is regarded as a promoter of atherosclerosis and initiator of 
thrombosis (Ross and Glomset, 1976b). T-cells and monocytes from the blood 
infiltrate the intima, leading to the development of an inflammatory reaction. 
This reaction may be pro-atherosclerotic by increasing apoptosis of vascular 
SMC (Geng et al., 1996), decreasing collagen synthesis (Amento et al., 1991), 
or inducing matrix metalloproteinase (MMPs) production (Henney et al., 1991; 
Galis et al., 1994a; Galis et al., 1994b). However, it may also be anti-
atherosclerotic, by affecting MMP secretion (Sarén et al., 1996), inducing nitric 
oxide production (Yan et al., 1996), or reducing SMC proliferation (Hansson et 
al., 1991). Initially, MDM may be beneficial in removing accumulated 
lipoproteins but later they may even be harmful by producing cytokines, free 
radicals, growth factors, and matrix-degrading enzymes. 
ASMC are often the dominating cellular component of the intimai lesion and 
may constitute as much as half of the plaque volume. Too many ASMC within 
the intima undoubtedly contribute to luminal narrowing and increased responses 
to vasoconstrictor stimuli (Folkow, 1987). However, too few ASMC and too 
little ASMC-derived ECM have been implicated as a cause of plaque 
vulnerability and rupture by providing too thin or fragile caps over the 
gelatinous lipid core (Davies et al., 1993; Falk et al., 1995; Fuster et al., 1998). 
A key role in intimai hyperplasia has been attributed to the platelet-derived 
growth factor (PDGF), a well-recognised mitogen for mesenchymal cells, 
including ASMCs. The main aims of this thesis were to establish a better 
understanding of the role of PDGF and its receptors (PDGF-Rs) in the cellular 
responses in the complex atherosclerotic plaque by studies in simplified in vitro 
systems. Increased knowledge of the expression of PDGF isoforms and their 
receptors may facilitate the development of therapies for a direct control of cell 
accumulation during plaque development. 
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THE VESSEL WALL 
A healthy/normal arterial wall consists morphologically of three distinct layers (Fig. 1). The innermost layer is the intima. This layer consists of 
ECM and has a barrier of endothelial cells located on the luminal side close to 
the blood flow. The ECM is an intricate network of macromolecules located 
between cells. It consists of a variety of proteins and polysaccharides. A layer of 
elastic fibers, lamina elastica interna, determines the border to the media, 
which is the middle portion of the arterial wall. The media consists mainly of 
diagonally arranged SMCs in a matrix of collagen, elastic fibers, and 
proteoglycans. 
LUMEN 
_ • • » • _• • ~| •*— Endothelial cells 
Lamina elastica interna C 
Smooth muscle cells MEDIA 
Lamina elastica externa 
Fibroblasts 
ADVENTITIA 
Vasa vasorum 
Fig. 1. Cross-section of a normal arterial wall. 
The outermost layer of the vessel is the adventitia which is often separated from 
the media by another layer of elastic fibers, the lamina elastica externa. The 
adventitia mainly consists of fibroblasts and loosely arranged SMCs, in between 
which ECM is interspersed. The adventitia also contains blood capillaries (vasa 
vasorum) which supply the peripheral arterial wall with nutrients and oxygen. 
13 
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The inner half is supplied by diffusion from the main vessel lumen (Ross and 
Glomset, 1976a). A gradual decrease in oxygen levels towards the centre of the 
media has been observed both from the luminal and the adventitial side (Jurrus 
and Weiss, 1977; Crawford et al., 1980; Crawford and Kramsch, 1988; Santilli 
et al., 1992). It has been suggested that human atherosclerosis may be initiated 
by occlusion of the vasa vasorum and concomitant hypoxia, resulting in a 
hyperplastic lesion composed mainly of SMCs (Barker et al., 1993). Hence, in 
some cases, atherosclerosis may be a disease of the outer layers of the arterial 
wall (van der Loo and Martin, 1997.) 
Several cell types are found within the arterial wall. They all contribute in their 
own way to the homeostasis of the normal arterial wall, but also play significant 
roles in the diseased vessel. A short introduction to the main cell types studied 
in vitro in this thesis is given below. 
Endothelial Cells (EC) create a single-layered barrier to the lumen, which 
regulates molecular and cellular movements across the vessel wall thus creating 
an adaptable life-support system (Holvoet and Collen, 1997). The normal 
endothelium constitutes a non-adhesive surface for both platelets and 
monocytes as well as an anti-coagulant surface. EC produce several important 
factors such as nitric oxide (NO) (Palmer et al., 1987) and cell adhesion 
molecules (Cybulsky and Gimbrone, 1991). When the endothelial barrier is 
compromised or injured, surrounding EC start to spread and migrate into the 
compromised area (Ross and Glomset, 1976a). This process may elicit the 
secretion of growth factors and cytokines, which stimulate neighbouring cells 
(Ross, 1993; Holvoet and Collen, 1997). 
Smooth Muscle Cells (SMCs) form diagonally arranged layers of differentiated/ 
quiescent/contractile cells within the media. Due to exogenous stimuli, such as 
growth factors and cytokines, they may be induced to change their phenotype. It 
has been shown that T-cells through the release of IFN-y induce 
dedifferentiation (proliferation) of SMCs (Rolfe et al., 1995). SMC 
dedifferentiation can also be stimulated by macrophages in vitro (Rennick et al., 
1988). This could be due to macrophage-derived heparan-sulfate degrading 
enzymes which have been shown to induce the dedifferentiated phenotype in 
SMCs (Campbell et al., 1992). Proteoglycans in the arterial wall may also affect 
SMC phenotype. Heparin and heparan-sulfate proteoglycans inhibit phenotypic 
changes in SMCs thus rendering them in a quiescent/differentiated state (Fager 
et al., 1988; Fager et al., 1989; Bingley et al., 1998), whereas differential 
expression of versican (Lemire et al., 1996) and perlecan (Weiser et al., 1996) 
in SMCs might contribute to different phenotypes. PDGF and/or serum 
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stimulates SMC to dedifferentiate and proliferate in vitro (Fager et al., 1988; 
Fager et al., 1989; Fager et al., 1992). 
Monocytes/Macrophages (MDM). Classically white blood cells are grouped into 
three main categories on the basis of their appearance in the light microscope; 
granulocytes, monocytes, and lymphocytes. Together with the neutrophils, 
macrophages are the main "professional phagocytes" of the body. As such, 
macrophages digest invading microorganisms and foreign bodies and remove 
damaged cells from tissues. When monocytes leave the blood stream and enter 
the vessel wall through the compromised endothelial cell layer, they start to 
differentiate into macrophages (Daugherty and Rateri, 1993; Ross, 1993). 
Macrophages are sources of cytokines, growth factors, free radicals, and matrix-
metalloproteinases (MMPs). Oxidised low density lipoproteins (LDL) are taken 
up by differentiated macrophages through the scavenger receptor (Sparrow et 
al., 1989). This eventually leads to foam cell formation within the vessel wall 
(Ross, 1993). A lipid core starts to develop within the atherosclerotic plaque, 
and results in increasing plaque vulnerability. 
DEVELOPMENT OF ATHEROSCLEROSIS 
The name "atherosclerosis" implies that mature plaques typically consist of two components; the soft, lipid-rich atheromatous "gruel" core (atherosis) 
and the hard, collagen-rich sclerotic/fibrous tissue cap (sclerosis) (Falk et al., 
1995). By deduction from animal studies, it has been suggested that the 
atherosclerotic lesion progresses through three main stages; 1) fatty streaks, 2) 
fibrolipid lesions, and 3) complicated lesions (Daugherty and Rateri, 1993) (Fig. 
2). Furthermore, all three stages may coexist in the same individual and even 
within the same artery. The earliest type of lesion, the fatty streak (Fig. 2A), 
may be found also at young age (Napoli et al., 1997). It is mainly an 
inflammatory lesion, consisting of MDM and T-cells (Stary et al., 1994). The 
fatty streak develops when monocytes from the blood migrate into the 
subendothelial space, differentiate into macrophages and start to phagocytose 
oxidised LDL via the scavenger receptor which converts them to foam cells. 
The lipid deposition progresses further into the fibrolipid lesion (Fig. 2B) by 
creating an acellular gruel core region. A fibrous cap is formed and stabilised 
through SMC proliferation, as discussed below. Thrombus and ulceration of 
atherosclerotic lesions subsequently results in the final stage, a complicated 
lesion (Fig. 2C) (Daugherty and Rateri, 1993). A rupture, often at the shoulder 
regions of the plaque, eventually leads to thrombotic occlusion and acute 
clinical complications. This occurs most frequently where the fibrous cap is 
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thinnest, most heavily infiltrated by foam cells, and therefore weakest (Falk et 
al., 1995; Fuster et al., 1998). Local MMPs have been implicated in this 
process. 
The first theories about the mechanisms of atherosclerosis appeared in the early 
19th century. Two simultaneously occurring hypotheses were the incrustation 
hypothesis and the lipid hypothesis. The incrustation hypothesis (von 
Rokitansky, 1852) suggested that intimai thickening resulted from fibrin 
deposition and subsequent fibroblast organisation with the accumulation of 
lipid being a secondary event. The lipid hypothesis (von Virchow, 1856) 
suggested that lipid accumulated within the arterial wall because the 
mechanisms of lipid deposition predominated over those of removal. These 
theories were eventually integrated in the more complex response-to-injury 
theory in 1976 (Bondjers et al., 1976; Ross and Glomset, 1976a). This theory 
hypothesised that some kind of injury was a prerequisite for the initiation of the 
disease and that the normal healing procedure went awry due to unfavourable 
conditions such as hyperlipidemia. The complexity of atherosclerosis became 
evident when it was realised that the immune system is actively involved in the 
progression of the disease (Hansson et al., 1989; Libby and Hansson, 1991). In 
fact, the cellular interactions in atherogenesis are similar to those in other 
chronic inflammatory-fibroproliferative diseases, such as cirrhosis and 
rheumatoid arthritis (Ross, 1999). In recent years, the inflammatory component 
of atherosclerosis has been given much attention. It is now recognised that these 
events are able to contribute to the disease also without obvious injury to the 
endothelium. Within the immune system both positive and negative signals may 
be induced. Details on the immunological mechanisms in the induction of 
atherosclerosis have been reviewed by Hansson (1997). 
A correlation between the incidence of atherosclerosis and the presence of pro­
inflammatory microorganisms has been shown. However, there is no direct 
evidence that these organisms can cause the lesions of atherosclerosis (Libby et 
al., 1997). Very recently it was shown that both chlamydial and human heat 
shock protein 60s (HSP 60) colocalise in human atheroma and induce tumour 
necrosis factor-a (TNF-a) and MMP production by MDM (Kol et al., 1998). 
Both HSP 60 activate human EC, SMC, and MDM, thus contributing to 
atherogenesis (Kol et al., 1999). Furthermore, MMP may contribute to plaque 
vulnerability by degrading the ECM of the fibrous cap (Schönbeck et al., 1997). 
Immunocompetent cells (i.e. T-cells and MDM) infiltrate atherosclerotic 
plaques of all stages. Activation of T-cells results in secretion of cytokines such 
as IFN-y and TNF-a and -ß. Apoptosis of SMC is induced by a combination of 
IFN-y and TGF-ß (Geng et al., 1998). This is mediated by the 
16 
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A. Fatty Streak 
Endothelial cells 
Lamina elastica interna 
Q Monocytes 
O 
Macrophages/Foam cells 
Smooth muscle cells 
INTIMA 
MEDIA 
C. Complicated Lesion 
Thrombus 
Fig. 2. Developmental stages of atherosclerotic lesions. 
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generation of gelsolin, a target for the death-promoting cysteinyl-protease 
caspase-3. Gelsolin-deficient SMC showed resistance to apoptosis induced by 
these inflammatory cytokines (Geng et al., 1998). Gelsolin may thus contribute 
to plaque vulnerability. 
Although increasing evidence support the involvement of inflammatory and 
immunological processes in atherosclerosis, principles for cell-cell signalling in 
atherosclerosis have not been elucidated in detail. A possible mediator of cell-
cell communication was discovered recently when it was found that cells within 
the lesion express elevated levels of the immune mediator CD40 and its ligand 
CD40L (Mach et al., 1997; Schönbeck et al., 1997). An important role of CD40 
in atherogenesis was supported by recent findings in hyperlipidemic 
apolipoprotein E-deficient mice, in which blocking of CD40 by antibodies 
reduced their inherited lesion formation (Mach et al., 1998). 
Central to the development of the atherosclerotic plaques is the accumulation of 
LDL, ASMC, MDM, T-cells, and ECM. Initially, it was thought that only SMCs 
proliferated within atherosclerotic lesions. It is likely, however, that replication 
of MDM and T-cells may also be important (Rosenfeld and Ross, 1990). 
Furthermore, both native and oxidised LDL may stimulate the production of 
PDGF-A chain (see below) transcripts and surface expression of PDGF-Rs in 
human SMC (Stiko-Rahm et al., 1992). This suggests that LDL may indirectly 
influence the growth of PDGF-responsive SMCs. This provides a potential link 
between hypercholesterolemia and activation of SMC growth. Macrophages 
produce cytokines, including PDGF, which may promote SMC migration from 
the media to the intima and their subsequent proliferation within the growing 
lesion. 
The involvement of PDGF in intimai hyperplasia has been demonstrated in 
several in vivo experiments (George et al., 1996; Banai et al., 1998). However, 
it has also been suggested that the proliferative process is initiated by basic 
fibroblast growth factor (bFGF) and that PDGF is more important for 
maintaining than initiating the proliferative process by serving as chemotactic 
attractant and mitogen for SMCs (Reidy et al., 1992). The importance of bFGF 
in this context was partially confirmed when rat SMC proliferation could be 
inhibited through the binding of heparin to bFGF (Lindner et al., 1992). In vivo 
data from rat carotid arteries with intimai lesions, showed that reinjury is not 
controlled by bFGF, suggesting that other factors are important for the second 
proliferative response (Koyama and Reidy, 1997). Hence, it may be possible 
that one of these factors is PDGF, which acts as the secondary response after the 
cells have been "triggered" by FGF. 
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PDGF ISOFORMS AND THEIR RECEPTORS 
PDGF Isoforms 
PDGF was first isolated from platelets, hence its name. Today, it is well recognised that this growth factor is produced by a variety of cells. PDGF 
belongs to a superfamily of its own, which also includes vascular endothelial 
growth factor (VEGF), a mitogen for endothelial cells (Keck et al., 1989). 
Recently, a connection between members of the PDGF family was established 
by Edelberg et al. (1998), who showed that PDGF-AB/PDGF-
Ra communication induces expression of VEGF and one of its receptors, which 
are critical components of normal angiogenesis. 
Biologically active PDGF is a homo- or heterodimer of two similar but distinct 
disulphide-linked A- and B-chains. Hence, mature PDGF occurs as three 
chimeric isoforms: PDGF-AA, -AB, and -BB (Fig. 3). The PDGF chains have a 
high amino acid homology of approximately 50%. All isoforms have been 
isolated from various sources including platelets, vascular SMCs (VSMCs), EC, 
and macrophages (Stroobant and Waterfield, 1984; Collins et al, 1985; Heldin 
et al., 1986; Barrett and Benditt, 1988; Hammacher et al., 1988). 
A A AB BB 
Fig. 3. Naturally occurring PDGF isoforms. 
The PDGF-B chain was mapped to the short arm of chromosome 21; region 
12.2-13.1 (22ql2.2-13.1) (Dalla Favera et al., 1982; Swan et al., 1982) while 
the human PDGF-A chain has been mapped to the long arm of chromosome 7 
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(7p) (Stenman et al., 1992). The general structure of these two genes is similar, 
with seven analogous but differently spaced exons (Bonthron et al., 1988; 
Rorsman et al., 1988). 
PDGF occurs as a cell-retained and a secreted form. Due to alternative splicing, 
either exon 6 or 7 encodes the carboxy-terminus of the PDGF-A chain 
(Betsholtz, 1993). The alternative splicing of the PDGF-A chain mRNA results 
either in a long isoform (PDGF-AL) containing a basic amino acid sequence 
corresponding to exon 6 or in a short isoform (PDGF-AS) lacking this basic C-
terminus (Fig. 3). The basic C-terminal tail gives PDGF-AL cellular and matrix 
retention properties (Pollock and Richardson, 1992; Andersson et al., 1994) by 
binding to heparin-like glycosaminoglycans (GAGs) (Fager et al., 1992; Lustig 
et al., 1996; Lustig et al., 1999). Although the transforming effects of PDGF are 
independent of this cell retention (LaRochelle et al., 1990), PDGF-AL may 
exhibit higher mitogenic activity (Collins et al., 1987) possibly due to increased 
efficiency of assembly and secretion (Bonthron et al., 1988). It has also been 
suggested that the basic C-terminal sequence is responsible for targeting a non-
secreted form of the PDGF-A chain to the nucleus (Maher et al, 1989). 
In contrast, PDGF-B is synthesised only as a long isoform containing an exon 6-
encoded basic C-terminal peptide, which has been implicated in membrane 
translocation (LaRochelle et al., 1991; Östman et al., 1991; Raines and Ross, 
1992). However, proteolytic cleavage then removes the basic "tail" after 
membrane translocation and the short mature PDGF-B isoform is released 
(Johnsson et al., 1984). 
The GAG retention motif of PDGF is conserved in all species sofar 
investigated, supporting the importance of this sequence. Related VEGF 
members also have a conserved alternative splicing of exon 6, which further 
implies a significant biological role for this phenomenon (Keck et al., 1989; 
Leung et al., 1989; Betsholtz et al., 1990; Maglione et al., 1993; Olofsson et al., 
1996). 
The in vivo importance of the different PDGF chains has been extensively 
studied in knock-out (KO) mice. Despite the high lethality of homozygous 
PDGF KO, it has been shown that PDGF-A KO have a severely defective 
alveogenesis (Boström et al., 1996; Lindahl et al., 1997b), whereas PDGF-B 
deficient mice demonstrate renal, cardiovascular, and haematological 
abnormalities with pericyte loss and microaneurysm formation (Levéen et al., 
1994; Lindahl et al., 1997a). Thus, PDGF is a key regulator of connective tissue 
cells also in embryogenesis. 
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Regulation of PDGF Gene Expression 
A general survey of the different signals controlling PDGF expression has been given by Dirks and Bloemers (1996). Despite the role of PDGF in 
several physiologic and pathophysiologic processes, the molecular mechanisms 
controlling the transcription of its genes are still poorly understood. The 
transcription of the PDGF genes seems to be governed by complex interactions 
of both positive and negative regulatory influences (Kaetzel et al., 1993). The 
regulatory mechanisms in PDGF production is further discussed in Results and 
Discussion. 
PDGF Receptors 
PDGF exerts its mitogenic and chemotactic functions by binding to specific cell surface receptors composed of two subunits; a (PDGF-Ra) and ß 
(PDGF-Rß). The gene for PDGF-Rß was cloned in 1988 (Claesson-Welsh et al., 
1988; Gronwald et al., 1988) and that of the PDGF-Ra in 1989 (Claesson-
Welsh et al., 1989a). This allowed structural comparisons between the two 
receptor subunits (Claesson-Welsh et al., 1989b). 
The PDGF-Rs belong to the receptor tyrosine kinase (RTK) subclass III which 
belongs to the RTK superfamily. Today, there are five known RTK class III 
genes; the PDGF-Ra, the PDGF-Rß, and the receptors for human proto-
oncogene c-kit, proto-oncogene fms, and murine flt-3 (Coussens et al., 1986; 
Yarden et al., 1987; Gronwald et al., 1988; Matsui et al., 1989; Rosnet et al., 
1991). Although closely related to the class III subclass, the VEGF receptors 
(VEGF-Rs) constitute a separate subfamily and form the RTK class V (Rousset 
et al., 1995; Kondo et al., 1998). Interestingly, the genes for both subfamilies 
are located in three clusters on different chromosomes. Two of these clusters 
contains one class V gene and two downstream class III genes. Only one class 
Y gene and one class III gene have been found in the third cluster. The absence 
of a second gene encoding a class III receptor has arisen speculations about a 
third, yet unidentified, PDGF-R (André et al., 1992; Rousset et al., 1995). 
PDGF isoforms bind to the corresponding PDGF-R subunits in a specific 
manner (Claesson-Welsh et al., 1989a; Seifert et al., 1989). The extracellular 
domain of the PDGF-Ra binds both PDGF-A and B-chains with high affinity, 
whereas the PDGF-Rß only binds the PDGF-B chain with high affinity (Fig. 4). 
The high affinity sites for PDGF-AA and -BB in the PDGF-Ra extracellular 
21 
Expression of Platelet-Derived Growth Factor Isoforms and Their Receptors 
domain are probably structurally distinct (Heidaran et al., 1992). Furthermore, 
specific regions in the PDGF molecule are involved in receptor binding. Thus, 
mutational analyses have previously shown that loops 1 and 3 of PDGF are 
important for receptor binding (Clements et al., 1991; Jaumann et al., 1991). 
Further, it was shown that the loop 2 region is more important for binding to 
PDGF-Rß than PDGF-Rot (Andersson et al., 1995). 
A-chain B-chain 
PDGF 
/ 
/ 
/ 
/ 
/ 
/ 
/ 
PDGF-R 
a-subunit ß-subunit 
Fig. 4. The PDGF chains and their binding specificity 
to the corresponding PDGF-R subunits. 
The importance of the PDGF-R subunits in vivo has been extensively studied 
through the development of KO mice for both subunits. Homozygous PDGF-Rß 
KO die at or shortly after birth and exhibit abnormal kidney development as 
well as haematological defects similar to PDGF-B KO (Soriano, 1994). PDGF-
Ra KO show that this receptor subtype is essential for neural crest development 
and only heterozygous KO survive (Soriano, 1997). These observations support 
several of the findings in the corresponding ligand KO and confirm the vital 
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importance of normal PDGF ligand and receptor interactions also during 
embryonic development. 
Regulation of PDGF Receptor Gene Expression 
Knowledge about the regulatory elements involved in the transcription of the PDGF-R genes has been limited so far. Alternative transcripts for 
both PDGF-Ra and -Rß have been found (Vu et al., 1989; Afink et al., 1995; 
Kraft et al., 1996). However, the role of these truncated proteins encoded by 
alternative PDGF-R transcripts is not known, since none of them have been 
detected in vivo. Transcriptional regulation of PDGF-R is described in further 
detail in Results and Discussion. 
PDGF Signalling Through Its Receptors 
The PDGF-Rs exist as free transmembraneous monomers in the absence of ligand (Herren et al., 1993). When a dimeric PDGF molecule first binds 
one subunit and then another, a dimerisation of these PDGF-R subunits occurs 
(Westermark and Heldin, 1991). It is still not clear if this dimerisation only 
involves bridging of the two receptor subunits by one dimeric PDGF molecule, 
or whether the receptor molecules directly engage in dimerisation (Westermark 
and Heldin, 1991). Dimerisation of receptor subunits by binding to dimeric 
PDGF is a prerequisite for the mitogenic signal transduction and is coupled to 
kinase activation and transphosphorylation of receptor molecules (Westermark 
and Heldin, 1991). There are two possible roles for this dimerisation. Either, 
kinase activity is triggered by conformational changes, which unfold active 
sites, or the PDGF-R molecules are brought together, which permits 
transphosphorylation between the two kinase domains of the subunits through a 
basal kinase activity (Westermark and Heldin, 1991). Receptor activation 
results in phosphorylation of tyrosine residues. These phosphotyrosines 
participate in binding of downstream signal transduction molecules, which 
recognise specific phosphorylated tyrosines and adjacent amino acid residues 
(Koch et al., 1991). Most of these sites are outside the kinase domains. These 
molecules belong to a family of Src homology 2 (SH2) domain molecules 
(Kochetal., 1991) (Fig. 5). 
The binding of PDGF to its receptor elicits an intracellular signalling cascade. 
Early, it was discovered that PDGF-A and -B chains differ in transforming 
potential (Beckmann et al., 1988), suggesting that both chains have unique and 
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specific functions within the cell (Mendoza et al., 1990; Reuterdahl et al., 1993; 
Inui et al., 1994). It is now clear that different pathways are activated depending 
on the PDGF isoform (Kondo et al., 1993). Further, the two receptor subunits 
activate both common and unique signal transduction pathways (Eriksson et al., 
1992; Inui et al., 1994). This may explain why different isoforms of PDGF may 
exert different functions within the target cell. 
PDGF-BB 
CELL SURFACE PDGF-Rß 
cdc42 
STAT 
PI3-K 
À PRC 
STAT 
TATS 
NUCLEUS 
Fig. 5. Simplified model of signal transduction pathways for PDGF-Rß. 
Suggested pathways for proliferation (dark grey) and migration 
(light grey) are depicted. (Modified from Lindahl (1998)). 
The very rapid and immediate response to PDGF binding includes intracellular 
Ca fluxes and cytoplasmic pH changes (Heldin et al., 1987). Very soon after 
stimulation, these changes are followed by cytoskeletal rearrangements. The 
long term responses to PDGF stimulation include migration, proliferation, and 
differentiation of target cells. Distinct signal transduction pathways are 
involved when human arterial SMCs migrate or proliferate upon ligand 
stimulation (Bornfeldt et al., 1995) (Fig. 5). 
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PDGF-Rs signal through at least five signal transduction pathways, which are 
all shared with other RTK and additional receptor types (Claesson-Welsh, 
1996). PDGF-Rß has been more extensively studied than PDGF-Ra. Several 
signal transduction molecules interact with the PDGF-Rß (Fig. 5). These are 
signal transduction molecules with enzymatic activity such as phosphatidyl-
inositol 3-kinase (PI3-K), phospholipase C-y (PLC-y), the Src family of tyrosine 
kinases, the tyrosine phosphatase SFIP-2, the GTPase activating protein of Ras 
(GAP), as well as several adaptor molecules such as growth factor receptor 
bound protein (GRB2), She, Nek, GRB7, and Crk, and signal transducers and 
activators of transcription (STATs) (Claesson-Welsh, 1996; Heldin et al., 1998). 
All signal transduction molecules have different roles in PDGF induced 
proliferation and migration. A similar detailed information on PDGF-Ra 
signalling is not available today although a few downstream signalling 
molecules have been identified (Heldin et al., 1998). 
PDGF and SMCs in Atherogenesis 
The involvement of PDGF in intimai hyperplasia has been shown by several in vivo experiments. Thus, PDGF contributes to neointimal formation after 
balloon angioplasty in pigs (Banai et al., 1998) and has also an essential role in 
human SMC migration into the neointima of the saphenous vein (George et al., 
1996). Other in vivo experiments show that the administration of an anti-PDGF 
antibody inhibited neointimal SMC accumulation after angioplasty in rats 
(Ferns et al., 1991). Also, introduction of a gene construct encoding PDGF-B 
chain into intimai cells of normal porcine iliofemoral arteries resulted in vivo in 
VSMC proliferation and vascular stenosis (Nabel et al., 1993). All these 
experiments taken together strongly suggest that PDGF is involved in the 
proliferative process. 
PDGF-induced SMC proliferation has a pivotal role in developing 
atherosclerotic lesions. Although initial proliferation contributes to plaque 
development and narrowing of the arterial lumen, later this proliferation may 
contribute to plaque stabilisation by creating a fibrous cap over the lesion. This 
makes the lesion less prone to rupture. Plaque stability depends on the structural 
integrity of its ECM skeleton. SMC contribute to this matrix by producing large 
amounts of collagen and proteoglycans. In fact, collagen and proteoglycan 
syntheses are increased when SMC change from the contractile to the synthetic 
state in association with proliferation (Ang et al., 1990; Fager et al., 1995). A 
role for SMC proliferation in plaque stabilisation is supported by the 
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observation that disrupted aortic caps contain fewer SMCs and less collagen 
than intact caps (Wagner et al., 1980; Davies et al., 1993). 
Thus, SMC proliferation may have dual effects during lesion development 
depending on the stage of the lesion. Plaque stability may also be achieved by 
reducing plasma lipids, which reduces local inflammation and lipid 
accumulation (Libby and Aikawa, 1998). Instability of the plaque is also a result 
of macrophage accumulation, activation, and apoptosis of cells (Lee and Libby, 
1997). Growth factors may contribute to lesion stabilisation by acting as 
"survival factors" which prevent cells within lesions from undergoing 
apoptosis. Thus, PDGF may partially reverse apoptosis in human VSMC and 
subsequently increase plaque stability (Bennett et al., 1995). 
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AIMS 
The aims of this thesis were to study the in vitro regulation of PDGF and PDGF-R expression in the main cell-types represented in the human 
atherosclerotic lesion. Specifically, I wanted to investigate 
• If the expressions of PDGF isoforms and their receptors are affected by 
changes in cell phenotype 
• If this expression is modulated by exogenous cytokines 
• If different PDGF homodimers may affect major cellular events, such as 
proliferation of hASMC and migration of hMDM, which are known to 
occur in the atherosclerotic lesion 
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RESULTS AND DISCUSSION 
This thesis focuses on the expression of PDGF and its cognate receptors in the main cell types occurring in the atherosclerotic lesion; SMC and 
MDM. It also provides observations on the effects of phenotypic changes and 
cytokines on these expressions. Further, it studies PDGF expression during 
phenotypic changes of EC as well as migration of MDM and proliferation of 
SMC in response to PDGF. An overview of the different parts constituting this 
thesis is shown in Fig. 6. 
Fig. 6. Schematic representation of the parts of this thesis. 
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Influence of Phenotype on PDGF and PDGF-R Expression 
Human Arterial Smooth Muscle Cells 
The accumulation of ASMC in the intima is accompanied by a mitogen-induced change in cell phenotype (Bobik and Campbell, 1993). Growth-
stimulated SMCs change their differentiated, contractile phenotype to the 
dedifferentiated, synthetic state, which is associated with proliferation (Fager et 
al., 1988; Fager et al., 1989). In the present study, hASMC (positive staining for 
SMC-specific a-actin) were isolated from the inner media of human uterine 
arteries (Papers I, II, III). These cells were isolated by explantation and treated 
as described previously (Fager et al., 1988). Secondary (passage 5 to 8), 
untransformed, and mycoplasma-free cells were used throughout these studies. 
Different SMC phenotypes (quiescent, proliferating, and confluent) were 
established in vitro as described elsewhere (Fager et al., 1988; Fager et al., 
1989). The different phenotypic states of hASMCs used in Papers I ( Figs. 6 and 
7) and II (Figs. 6 and 8) were chosen to mimic the in vivo situation in 
developing lesions. 
PDGF mRNA Expression 
Messenger RNA levels were determined using a quantitative reverse-
transcriptase polymerase chain reaction (RT-PCR) as described (Paper II; Wang 
et al., 1989). At least 100 times higher expression of PDGF-A than PDGF-B 
mRNA was found in hASMC (Paper II). The PDGF-B mRNA expression was 
very low in hASMC compared to the other studied cell types. 
In the presence of serum, proliferating hASMC grossly decreased total PDGF 
mRNA levels (Paper II) and both PDGF isoform mRNAs were downregulated 
in confluent hASMC. Since PDGF-Rß mRNA was also downregulated in this 
phenotype (Paper I), these observations suggested that reduced production of 
endogenous PDGF isoforms and at least one of its receptors may contribute to 
growth arrest during confluency. 
Irrespective of phenotype, only a minor fraction of total PDGF-A mRNA 
consisted of PDGF-AL transcripts in hASMC. However, since hASMC are one 
of the major cell types within the arterial wall, which also expressed high levels 
of PDGF-A mRNA, the hASMC contribution to the PDGF-AL pool is probably 
substantial. A summary of PDGF expression during phenotypic changes of 
hASMC is given in Table 1. 
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PDGF-R Expression 
A phenotype-dependent expression of PDGF-R mRNAs was previously 
reported from studies on rat ASMC in vitro (Sjölund et al., 1990). The 
mitogenic stimulation of SMC depends on the concentration of mitogen and the 
abundance of appropriate receptors. 
Quantitative methods were established for the determination of PDGF-R mRNA 
(quantitative RT-PCR) and protein (quantitative ELISA) levels (Paper I). Our 
results showed that hASMC from all donors under all studied culture conditions 
(quiescent, proliferating, and confluent) expressed transcripts for both PDGF-R 
subunits. 
I N T I M A  
Smooth muscle cells 
M E D I A  
Fig. 7. Schematic representation of Paper I. 
The overall PDGF-Rß mRNA expression was much lower than that of PDGF-
Ra. This expression was affected by cell phenotype. PDGF-Ra mRNA levels 
were constantly high irrespective of phenotype, whereas those of PDGF-Rß 
varied with cell phenotype and were thus clearly affected by culture condition. 
Thus, confluent hASMC, cultured in the presence of serum, tended to 
downregulate PDGF-Rß mRNA. 
Quiescent hASMC expressed approximately a 13-fold excess of PDGF-Rß 
compared to PDGF-Ra protein (Paper I). The relationship between PDGF-Ra 
and -Rß protein expressions deduced from the quantitative determinations were 
indirectly confirmed using immunofluorescent staining on quiescent hASMC 
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(Fig. 7 in Paper I). The results showed again that the PDGF-Rß was highly 
expressed on the surface of quiescent hASMC compared to PDGF-Ra. When 
sparse cultures were stimulated to proliferate by serum, both PDGF-R proteins 
were downregulated over time. Although PDGF-Ra mRNA was unaffected by 
serum, the corresponding protein was highly downregulated. In contrast, PDGF-
Rß mRNA levels decreased upon serum stimulation which was accompanied by 
some decrease in corresponding PDGF-Rß protein levels. After 48 hours of 
serum stimulation, hASMC still showed an approximately 25-fold excess of 
PDGF-Rß protein compared to PDGF-Ra. Immunofluorescent staining of 
confluent hASMC cultures showed that PDGF-Rs were expressed on the 
surface of these cells even after prolonged serum-stimulation. PDGF-R 
expression during phenotypic changes of hASMC is summarised in Table 1. 
Table 1. Summary of PDGF and PDGF-R expression in hASMC. 
Results in SM are shown in relation to cells in SFM. 
hASMC 
Phenotype 
mRNA Protein 
Differentiated and 
quiescent 
(SFM) 
PDGF-A > PDGF-B 
PDGF-Ra > PDGF-Rß PDGF-Ra < PDGF-Rß 
Dedifferentiated and 
proliferating 
(SM) 
PDGF-A -
PDGF-Al -
PDGF-B i 
PDGF-Ra -
PDGF-Rß i 
PDGF-Ra 4, 
PDGF-Rß 1 
Confluent and 
quiescent 
(SM) 
PDGF-A i 
PDGF-Al -
PDGF-B i 
PDGF-Ra -
PDGF-Rß i 
Hence, our results suggest that the two PDGF-Rs are independently regulated. 
The discrepancies between PDGF-R mRNA (ratio ß/a of 1/100) and protein 
(ratio ß/a of 10/1) levels suggest additional regulatory mechanisms on the 
transcriptional/post-transcriptional level of PDGF-R gene expression in 
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hASMC. This is further discussed below. Only PDGF-Rß mRNA was affected 
by the phenotypic changes and this subunit was highly expressed on the protein 
level compared to PDGF-Rcx. However, PDGF-Ra protein was more sensitive 
to serum and was highly downregulated compared to PDGF-Rß protein upon 
serum stimulation. 
When monocytes from the blood enter the intima they start to differentiate into mature macrophages (Fig. 8). MDM were studied during 
differentiation from monocytes to macrophages in the presence of serum (Paper 
II) or as early hMDM in the absence of serum (Paper III and IV). Mononuclear 
cells were isolated from buffy coats by a Ficoll-Hypaque discontinuous gradient 
(Böyum, 1976) in Papers II, III, and IV. From an aliquot of this cell suspension, 
monocytes were isolated using magnetic beads on ice (Paper II). This was made 
to obtain unstimulated monocytes which were neither activated by plating nor 
serum-stimulation, and to provide the best possible basal value. Hence, 
Dynabeads M-450/CD14 were used for some isolations. The CD14 antibody 
specifically isolates monocytes and leaves them attached to the magnetic beads. 
From these cells, RNA was directly isolated. 
Human Monocyte-Derived Macrophages 
Monocytes Endothelial cells 
Paper II 
'
NTiATIQn 
iFEBA-nON 
Smooth muscle cells 
Macrophages 
Fig. 8. Schematic representation of Paper II. 
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PDGF mRNA Expression 
The mRNA levels were estimated with quantitative RT-PCR of PDGF isoforms 
(Paper II; Wang et al., 1989). A major peak in PDGF mRNA expression was 
seen after 3 days of serum-stimulation. Differentiation of monocytes to 
macrophages, in the presence of serum, increased both PDGF-A and -B 
mRNAs. Compared to unplated monocytes, this occurred already after one day 
in SM. Both PDGF isoform mRNAs were expressed at almost similar levels in 
hMDM after differentiation for 7 days in SM. This suggested that PDGF 
production was associated with serum-dependent differentiation of hMDM. 
This hypothesis was supported by the decreases in PDGF mRNAs in early 
hMDM which were maintained in SFM (Paper III). 
The differentiation of monocytes to macrophages increased the transcription of 
PDGF-Al from 10% to 40% of total PDGF-A. 
Table 2. Summary of PDGF and PDGF-R expression in MDM. 
Results for dedifferentiated early hMDM are shown as changes in 
PDGF/PDGF-R mRNA expression over time in culture. In 
differentiated hMDM, results for PDGF mRNA are shown in 
relation to the expression in unplated, dedifferentiated monocytes 
(Day 0 in Paper II) whereas PDGF-R expression is shown as 
changes over time in culture. 
hMDM 
Phenotype 
mRNA Protein 
Dedifferentiated cells 
early hMDM 
(SFM) 
PDGF-A i 
PDGF-Al t 
PDGF-B i 
PDGF-Ra > PDGF-Rß PDGF-Ra < PDGF-Rß 
Differentiated cells 
hMDM 
(SM) 
PDGF-A Î 
PDGF-AL t 
PDGF-B T 
PDGF-Rat 
PDGF-Rß -
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PDGF-R Expression 
Semi-quantitative RT-PCR of PDGF-R mRNA (Paper IV) showed that hMDM, 
in response to serum, upregulated PDGF-Ra mRNA during differentiation. A 
significant continuous increase compared to Day 1 was observed (P>0.002). In 
contrast, PDGF-Rß mRNA was not affected by hMDM differentiation and was 
expressed at a constant level during 7 days of culturing (P>0.4) (Fig. 9; 
unpublished results). 
Time (days) 
ra 
PDGF-Ra 
p< 0.002 
rs= 0.945 
n=8 
PDGF-Rß 
p > 0.4 
rs= -0.380 
n=8 
400 
Fig. 9. PDGF-R mRNA expression in differentiating hMDM. 
PDGF-R expression in each RNA sample was related to the 
expression of the house-keeping gene ß-actin. Results are 
shown as the mean of three donors, each run in triplicate. rs 
denotes Spearman 's rank coefficient. 
In early hMDM (plated monocytes cultured in SFM), PDGF-Ra mRNA was 
expressed at much higher levels than PDGF-Rß mRNA, as judged from semi­
quantitative RT-PCR analyses. In contrast, quantitative ELISA showed that 
PDGF-Ra protein levels were much lower than the corresponding levels of 
PDGF-Rß (Paper IV, Figs. 6 and 11). Generally, PDGF-Ra was expressed at 
high mRNA and low protein levels. These results were similar in hASMC 
(Paper I). Again, this suggested a complex transcriptional/post-transcriptional 
regulation of PDGF-Rs. Either may PDGF-Ra mRNAs be only partly 
processed to competent cell surface receptors, or cell surface receptors 
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efficiently internalised after binding endogenously produced PDGF by hMDM 
(Paper II). Such internalised receptor-ligand complexes would not have been 
recognised by the ELISA used in Papers I and IV. A summary of PDGF and 
PDGF-R expression in hMDM is given in Table 2. 
Human Adult Vein Endothelial Cells 
In case of an injury to the endothelium, EC start to proliferate and move into the damaged area. Proliferation is associated with dedifferentiation of 
hASMC and EC. Human adult vein EC (hAVEC) (positive staining for von 
Willebrand Factor) were isolated from stripped varicose veins. Cells in passage 
4 were cultured and studied in different phenotypes (proliferating and 
confluent). Human AVEC were used instead of arterial EC due to the difficulty 
in obtaining large amounts of human arterial EC. 
PDGF mRNA Expression 
Quantitative RT-PCR analyses showed that hAVEC expressed higher levels of 
PDGF mRNA compared to both hASMC and hMDM (Paper II, Figs. 6 and 8). 
Both PDGF isoforms were expressed at similar levels. In the presence of serum, 
proliferating hAVEC grossly increased total PDGF mRNA levels. Confluent 
hAVEC, still in the presence of serum, tended to downregulate transcripts for 
PDGF-A. 
Irrespective of phenotype, hAVEC produced 40% of total PDGF-A transcripts 
as PDGF-Al mRNA. A summary of PDGF expression in hAVEC during 
phenotypic change is given in Table 3. 
Table 3. Summary of PDGF expression in hAVEC. 
Results are shown as a comparison between the two 
phenotypes. 
hAVEC mRNA 
Phenotype 
Dedifferentiated and PDGF-A t 
proliferating PDGF-Al -
(SM) PDGF-B i 
Confluent and PDGF-A i 
quiescent PDGF-Al -
(SM) PDGF-B t 
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In summary, changes in cell phenotype modulated the expression of PDGF and 
PDGF-Rs in different cell types. Differences in estimated mRNA and protein 
levels for PDGF-Rs suggested that the expressions of these genes are governed 
by complex transcriptional/post-transcriptional mechanisms. 
In ASMC, serum induced dedifferentiation of cells. Thus, the presence of serum 
in proliferating (dedifferentiated) cultures of hASMC reduced PDGF-B mRNA 
as well as PDGF-R, compared to quiescent cells. This suggests that growth 
arrest in these cells could partially be caused by downregulation of PDGF-B and 
PDGF-Rs. 
In hMDM, serum stimulation resulted in cell differentiation. During this 
process, both PDGF-A and -B mRNAs were upregulated compared to unplated 
monocytes. Also the proportions of PDGF-AL mRNA were increased during 
differentiation. PDGF-Ra but not PDGF-Rß mRNA was upregulated by serum 
in hMDM. This raises possibilities of a physiological importance of these 
findings in vivo, and suggests that PDGF might be important during 
macrophage recruitment and differentiation in the intima. Our results support a 
specific role of PDGF isoforms in monocyte migration (see Migration of Early 
hMDM below). 
EC expressed highest PDGF mRNA levels compared to hASMC and hMDM. 
These cells also had the highest expression of PDGF-AL which constituted 40% 
of total PDGF-A mRNA. 
Influence of Cytokines on PDGF and PDGF-R Expression 
The cytokines in these studies were chosen on the basis of the criterion that they are produced by cells within the atherosclerotic lesion. Thus, aFGF, 
IL-6, and TGF-ß are produced by both hMDM (Rappolee and Werb, 1992; 
Brogi et al., 1993) and SMCs (Loppnow and Libby, 1990; Agrotis et al., 1994; 
Chotani et al., 1995), whereas IFN-y is secreted from activated T-cells in the 
lesions. Acidic FGF induces angiogenesis in vivo, is involved in differentiation 
of a variety of cells, and is a chemoattractant and mitogenic stimuli for EC in 
vitro (Vainikka et al., 1994). IL-6 is a pleiotropic cytokine which may both 
promote and inhibit cell growth and induce differentiation in a variety of cells 
(Narazaki and Kishimoto, 1994). TGF-ß has been implicated in various 
biological processes such as: growth and differentiation of cells, regulation of 
ECM protein production, an important role in the function and differentiation of 
the immune system, wound healing and tissue repair, as well as an important 
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role in embryogenesis (Gitelman and Derynck, 1994). IFN-y is responsible not 
only for macrophage activation, but also acts as an antiviral agent, induces the 
expression of many key molecules (class I and class II MHC antigens, nitric 
oxide synthase, and cytokines such as IL-1), and has been implicated to 
participate in the development of autoimmune diseases (Gray, 1994). 
All cytokine incubations were made under serum-free conditions in order to 
avoid interference from serum factors in the experiments. The viability of plated 
monocytes cultured for three days in SFM and SM was high and comparable 
between the media when checked daily by trypan blue exclusion and release of 
lactate dehydrogenase. 
Table 4. Influence of exogenous cytokines on PDGF expression in 
dedifferentiated hASMC in SFM. 
Results are shown as the expression in cytokine-stimulated cells 
compared to controls without cytokine stimulation. 
hASMC + 
Cytokines 
mRNA Protein 
IFN-y PDGF-A -
PDGF-Al t 
PDGF-B -
PDGF-AB -
TGF-ß PDGF-A t 
PDGF-AL t 
PDGF-B -
PDGF-AB t 
aFGF PDGF-A t 
PDGF-AL-
PDGF-B -
PDGF-AB -
IL-6 PDGF-A -
PDGF-AL_ 
PDGF-B t 
PDGF-AB t 
Human Arterial Smooth Muscle Cells 
PDGF Expression 
Messenger RNA levels were determined with a quantitative RT-PCR method 
(Paper II; Wang et al., 1989) and PDGF-AB protein levels with a commercially 
available PDGF-AB protein ELISA from R&D Systems. In differentiated 
hASMC, PDGF-A mRNA was increased by TGF-ß and aFGF whereas PDGF-B 
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mRNA was slightly increased by IL-6. Both TGF-ß and IL-6 increased PDGF-
AB protein secretion (Paper III, Figs. 6 and 10). Increased proportions of 
PDGF-Al mRNA were found in hASMC after IFN-y stimulation. The findings 
in hASMC were consistent with previous findings in EC where IFN-y 
upregulated PDGF-AL mRNA (Zhao et al., 1995). Although the relative 
increase in PDGF-AL mRNA in hASMC was small, the simultaneous increase 
in total PDGF-A in response to TGF-ß suggests that the absolute upregulation 
of PDGF-Al at the transcriptional level may be substantial in these cells. A 
summary of PDGF expression in cytokine-stimulated hASMC is given in Fig. 4. 
Early Human Monocyte-Derived Macrophages 
PDGF Expression 
PDGF mRNA and PDGF-AB protein levels were determined as described 
above for hASMCs. In early hMDM in SFM, PDGF-A mRNA was increased by 
IFN-y and PDGF-B mRNA by both IFN-y and TGF-ß (Paper III, Figs. 6 and 
10). Only TGF-ß increased PDGF-AB protein secretion significantly. Increased 
proportions of PDGF-AL mRNA were found only after TGF-ß stimulation. It 
has been shown previously that TGF-ß specifically upregulates PDGF-AL 
mRNA in EC (Zhao et al., 1995). 
Previous reports show that IFN-y increases PDGF-B mRNA (Wangoo et al., 
1993) and PDGF-BB protein (Badgett et al., 1996) in alveolar macrophages or 
downregulates both PDGF-A and -B mRNAs in hMDM (Kosaka et al., 1992). 
The discrepancy between our results in early hMDM and those of Kosaka et al. 
(1992) in MDM probably depends on differences in culture systems and 
phenotypic state of the cells. This possibility is supported by the observation 
that IFN-y has no effect on any PDGF isoform mRNA in transformed monocytic 
THP-1 cells (Nagashima et al., 1994). 
PDGF-R Expression 
Using a quantitative ELISA for PDGF-Rs as described in Paper I, we found 
that early hMDM increased both PDGF-Ra mRNA and protein upon IFN-y 
stimulation. TGF-ß had only minor effects on both PDGF-R subunits (Paper 
IV, Figs. 6 and 11). A summary of PDGF and PDGF-R expression in cytokine-
stimulated early hMDM is given in Table 5. 
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Fig. 10. Schematic representation of Paper III. 
In summary, the cytokine studies showed that the cytokines act in a cell type-
specific manner. Thus in hMDM, IFN-y-stimulation upregulated both PDGF-A 
and -B mRNAs, and also showed major effects on PDGF-R expression in these 
cells. TGF-ß only increased PDGF-B mRNAs but affected the proportions of 
PDGF-Al mRNAs which increased after TGF-ß stimulation. PDGF-AB protein 
secretion was induced by TGF-ß. 
In hASMC, PDGF-A mRNA levels were increased after stimulation with TGF-
ß and aFGF. Increased levels of PDGF-AL were induced by both IFN-y and 
TGF-ß. Only IL-6 upregulated PDGF-B mRNA expression in hASMC. 
Interestingly, apoptosis, which is a feature in advanced atherosclerotic lesions, 
is induced in VSMC by a combination of IFN-y and TGF-ß (Geng et al., 1998). 
Although this is mediated through the generation of gelsolin (c.f. Development 
of Atherosclerosis) one might speculate that the increase in PDGF could act on 
these cells as a "survival factor" thus rescuing them from undergoing apoptosis 
and thereby contribute to plaque stability. Thus, the balance between 
exogenous cytokines and PDGF expression may determine plaque stability. It 
has been shown that IFN-y alone cannot induce VSMC apoptosis but it induces 
cell death after simultaneous treatment with TNF-a and/or IL-Iß (Geng et al., 
1996). In vivo, several cytokines act simultaneously on target cells. 
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Table 5. Influence of exogenous cytokines on PDGF expression in early hMDM. 
Results are expressed compared to controls in SFM. 
hMDM + mRNA Protein 
Cytokines 
IFN-y PDGF-A t PDGF-AB -
PDGF-Al -
PDGF-B t 
PDGF-Ra t PDGF-Ra f 
PDGF-Rß - PDGF-Rß i 
TGF-ß PDGF-AL t PDGF-AB t 
PDGF-B t 
PDGF-R minor effects PDGF-R minor effects 
aFGF PDGF - PDGF-AB N.D. 
IL-6 PDGF - PDGF-AB N.D. 
Regulation of PDGF and PDGF-R Expression 
Regulation of PDGF Expression 
The results obtained in Papers II and III showed that the expression of PDGF-A and -B genes was independently regulated and depended on cell 
type, cell phenotype, and exogenous influences. 
Hence, the effects of cytokines varied with cell type in our studies. A cell type-
specific cytokine effect has also been reported by others (Gay and Winkles, 
1990; Winkles and Gay, 1991; Kosaka et al., 1992; Wangoo et al., 1993). It has 
been shown that TGF-ß increases PDGF-A mRNA levels in human fibroblasts 
(Paulsson et al., 1988) and VSMC (Majack et al., 1990), while it stimulates 
PDGF-B mRNA expression (Leof et al., 1986) or the expression of both 
isoforms (Kavanaugh et al., 1988) in other cells. IL-6 increases PDGF-A and -B 
chains in human umbilical vein EC (Gay and Winkles, 1990) or has no effect on 
PDGF-A transcripts in human saphenous vein SMCs (Winkles and Gay, 1991) 
or on PDGF-AB protein in astrocyte-enriched cultures (Ceccherini Silberstein et 
al., 1996). 
Independently regulated expression of PDGF-A and -B transcripts in other cell 
types has been reported previously (Goustin et al., 1985; Heldin et al., 1987; 
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Paulsson et al., 1987; Westermark and Heldin, 1991). Thus, while many tumour 
cell lines express either one or both of the PDGF isoform mRNAs (Heldin et al., 
1987; Westermark and Heldin, 1991) the PDGF-A mRNA seems to be 
predominantly expressed, for example, in skeletal myoblasts and fibroblasts 
(Sejersen et al., 1986; Paulsson et al., 1987) and PDGF-B mRNA in placental 
cytotrophoblasts (Goustin et al., 1985). 
Transcriptional regulation occurs due to 5'untranslated GC-rich sequences 
(UTS) which may influence gene expression by being potential sites for 
transcriptional regulatory activity (Bonthron et al., 1988). Such regions in the 
promoter of the PDGF-A gene have been shown to contain mechanical strain-
responsive elements to which the transcription factors early growth response 
gene product (Egr-1) and possibly Sp-1 binds (Wilson et al., 1998). 
The effects of shear stress on PDGF expression is interesting, since cells within 
the vasculature are constantly exposed to fluid mechanical forces generated by 
the pulsatory blood flow. Monocytes are subjected to such varying shear stress 
in the blood stream, at branch points of arteries due to turbulent blood flow and 
at sites of arterial narrowing due to increased flow velocity. Furthermore, 
atherosclerotic plaques preferentially occur at sites with turbulent flow and 
increased shear stress. Both PDGF-A and -B mRNA levels are strongly induced 
in response to shear stress in human umbilical vein EC (Hsieh et al., 1991). This 
is mediated by fluid-shear-stress responsive elements (SSRE) in the promoters 
for both PDGF-A and PDGF-B genes, which bind Egr-1 (Khachigian et al., 
1996; Khachigian et al., 1997). It is now recognised that the induction of Egr-1 
is a common theme in vascular injury (Khachigian and Collins, 1997). 
Another stress-related influence on the cells within the vessel wall are the 
varying levels of oxygen concentration. Hypoxia results in both 
vasoconstriction and vascular remodelling (Leach and Treacher, 1995). These 
processes result in a narrowing of the blood vessel and reduced blood flow. 
During chronic hypoxia, SMC start to proliferate and ECM accumulates rapidly. 
This results in vessel wall remodelling. Oxygen is a potent regulator of PDGF-B 
gene transcription in human umbilical vein EC (Kourembanas et al., 1990). 
Further, it has been shown that the PDGF-A promoter region has potential for 
bi-directional activity (i.e. transcription of the gene can occur in both directions) 
which may regulate transcription. The bi-directional activity is influenced by 5 
UTR and the serum concentration in the culture medium (Takimoto and 
Kuramoto, 1994). It was later confirmed that serum regulates PDGF-A gene 
expression at the transcriptional level (Takimoto and Kuramoto, 1995). 
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Post-transcriptional regulation of gene expression is achieved through 
affecting mRNA stability and/or splicing of primary transcripts (Betsholtz, 
1993). Messenger RNA degradation in eukaryotic cells is a common theme in 
the regulation of gene expression. Messenger RNA instability is determined by 
several elements, including the presence of AU-rich 3'-sequences (Sachs, 
1993). Both the PDGF-A and -B chain mRNA contain such AU-sequences in 
their 3'-UTS with putatively destabilising functions (Betsholtz, 1993). 
Furthermore, the 5'-UTS of the PDGF-B mRNA are involved in determining 
degradative pathways for alternate mRNAs (Fen and Daniel, 1991). 
Translational regulation by a reversible binding of RNA/protein interaction in 
the 5'-UTS of the mRNA may be a general theme for regulating gene 
expression (Melefors and Hentze, 1993). It has been shown for PDGF-B mRNA 
that 5'-UTS are involved in inhibiting translation (Ratner et al., 1987; Rao et 
al., 1988). 
In our studies, the changes in PDGF mRNA levels did not always correlate with 
protein secretion in a very consistent way (Paper III). This could be due to a 
short half-life of the mRNA, which may reduce protein translation. Since the 
applied ELISA only determines heterodimeric PDGF-AB protein, the secretion 
of homodimeric PDGF-AA and -BB protein will not be detected. It is not 
known whether dimerisation of PDGF-A and/or -B monomers occur at random 
or if it is regulated. For example, increased levels of PDGF-A mRNA might 
lead to preferential formation of PDGF-AA and this will not be detected by the 
PDGF-AB ELISA. Furthermore, receptor-ligand internalisation due to autocrine 
stimulation could reduce PDGF protein in the cell culture supernatants. Finally, 
the applied ELISA only determines secreted PDGF-AB, thus cell-associated 
PDGF-AB is not detected with this assay. 
Regulation of PDGF-R Expression 
rranscriptional regulation has been shown to occur for PDGF-Rs. Thus, the PDGF-Ra gene contains at least two promoters in its genomic sequence, 
which are responsible for different transcripts (Afink et al., 1995; Kraft et al., 
1996). Developmentally regulated PDGF-Ra transcripts lacking exon 14 have 
also been reported (Mosselman et al., 1994). A similar pattern was observed for 
PDGF-Rß where different forms of transcripts for this subunit are produced, 
either due to alternative usage of two transcriptional promoters or to post-
transcriptional processing (Vu et al., 1989). 
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One possible explanation for the discrepancies between PDGF-R mRNA and 
protein levels in Papers I and IV is the occurrence of PDGF-Rß mRNA s and 
proteins truncated in their intracellular domains. Such truncated forms could 
have been detected with the antibodies used in our ELISA but not with the RT-
PCR primers used for determining mRNA levels. However, sofar only PDGF-R 
ß mRNA s with extracellular domain deletions have been detected (Vu et al., 
1989). This provides another explanation to our results, if similar truncated 
forms of PDGF-Ra transcripts occurred. Such species would not have been 
detected by our ELISA antibodies. RT-PCR experiments were thus performed 
with several other primer pairs located in different regions of the PDGF-Ra 
sequence (Paper I). Our findings were indirectly compatible with the possibility 
of alternative promoter usage during transcription of the PDGF-Ra gene in 
hASMC resulting in PDGF-Ra with truncated extracellular domains (Paper I). 
The results in Papers III and IV show that several cytokines affect both PDGF-
R and PDGF expression. The finding that IFN-y upregulated both PDGF-A and 
PDGF-Ra in early hMDM suggests that this cytokine may have potential 
importance during early hMDM recruitment to sites of injury and inflammation. 
This results in increased PDGF expression and enhanced responsiveness to 
PDGF by early hMDM. 
The mechanism behind the stimulatory effect of IFN-y in early hMDM is 
unclear. It was found previously that the action of IFN-y is mediated through the 
Jak/STAT pathway and phosphorylation of STAT1 leads to dimerisation of 
STAT proteins and their translocation to the nucleus (Fig. 5). Here, the STAT1 
complexes bind to IFN-y Activated Sequences (GAS), which leads to 
transcriptional activation of the target gene (Brown, 1998). The inability of 
STAT1 KO mice to respond to IFN-stimuli, confirms that STAT1 has a crucial 
and obligate role in IFN-y signalling (Durbin et al., 1996; Meraz et al., 1996). 
Interestingly, both PDGF-Ra and PDGF-A contain STAT-binding sites in their 
promoter regions, suggesting that this could be a possible mechanism of the 
IFN-y action in early hMDM. Further, it was previously shown that PDGF-BB 
directly activates the transcription factor STAT1 (Yamamoto et al., 1996), and 
that PDGF-BB through the interaction with PDGF-Rß phosphorylates multiple 
Jak family kinases and STAT proteins (Vignais et al., 1996). Finally, IFN-y also 
potentiates the DNA-binding activity of STAT1 in response to PDGF, resulting 
in increased DNA synthesis (Marra et al., 1996). 
In TGF-ß-stimulated hASMC, both PDGF-A mRNA and PDGF-AB protein 
were increased. Human MDM only upregulated PDGF-B mRNA in response to 
this cytokine. The mechanisms by which TGF-ß influences gene expression are 
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not well understood. It has been shown that the interaction of TGF-ß with its 
receptor phosphorylates the intracellular signal transduction molecule Smad2 
(Eppert et al., 1996; Souchelnytskyi et al., 1997). Phosphorylated Smads form 
heteroduplexes which translocate to the nucleus were they interact with specific 
DNA sequences thus resulting in gene transcription. Since little is known about 
TGF-ß-signalling sofar, it can not be excluded that the signalling through Smad 
proteins is not obligate and that other mechanism may be involved when TGF-ß 
exerts its cellular effects. 
Biological Implications of PDGF and PDGF-R Expression 
Proliferation ofhASMC 
It has been suggested that the responsiveness of cells to PDGF stimulation is regulated by the relative abundance of PDGF-Rs on the cell surface. Since 
proliferation rather than migration of SMCs plays a central role during the 
development of atherosclerotic lesions, we focused on the proliferative rather 
than the migratory response of hASMC to PDGF stimulation. Therefore, the 
responsiveness of hASMC to stimulation with different exogenous recombinant 
PDGF homodimers was studied (Paper I). Incorporation of thymidine into DNA 
was used to determine the proliferative effect of the different exogenously 
added PDGF homodimers. 
The proliferation of hASMC in response to different PDGF homodimers 
(PDGF-AAL, PDGF-AAS, and PDGF-BBS) showed a bimodal dose-dependence 
with increasing thymidine indices up to a maximum stimulation at about 5 
nmol/L of homodimer. A small but consistent dose-dependent decrease in these 
indices was observed above this concentration. Similar bimodal responses have 
been shown for bFGF-induced proliferation (Bono et al., 1997) and for PDGF-
induced migration (Koyama et al., 1994). A possible explanation for these 
observations is that the dimerisation of PDGF-R subunits required for optimal 
signal transduction is maximal at a molar ratio of 1:2 and that above this level, 
additional ligand will block signalling by monosaturating the PDGF-R subunits. 
Different exogenous PDGF homodimers induced rather similar proliferative 
responses in hASMC in spite of the 10-fold difference in abundance of PDGF-
Ra and PDGF-Rß proteins. The fact that the more abundant PDGF-Rß only 
responds to PDGF-B and that PDGF-A dimers were almost as efficient 
stimulators of DNA synthesis, may suggest that signalling through the PDGF-
Ra is more important for the proliferative response in hASMC. The similar 
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capacity of different PDGF homodimers to induce proliferation in hASMC 
suggested that the number of PDGF-Rs on the surface of these cells were not 
the only determinants for maximal cell stimulation. 
Prolonged SMC proliferation, as observed after reconstructive vascular surgery, 
could be achieved by the release of long PDGF isoforms from the ECM. 
Although the results in Paper II suggested that SMC express low concentrations 
of PDGF-AL, their total contribution to the PDGF-AL pool may be substantial 
due to the large number of these cells in the arterial wall. The comparatively 
high expression of PDGF-AL in hAVEC and its upregulation during monocyte 
differentiation may contribute to a depot of PDGF-AL in the arterial wall. The 
basic C-terminal extensions in the long PDGF isoforms may bind to GAGs in 
the surrounding matrix (Lustig et al., 1996; Lustig et al., 1999). This bound 
PDGF-Al can be released from its depot through the action of proteases such as 
coagulation factor Xa which has been shown in rat VSMCs (Ko et al., 1996). 
Recent data confirm that factor Xa by binding to high affinity sites exerts a 
mitogenic effect on VSMCs via the release of PDGF, which subsequently leads 
to the activation of MAP kinase, DNA synthesis, and cell growth (Herbert et al., 
1998). Dissociation of bound long PDGF isoforms may then induce cell 
proliferation through paracrine (cells stimulating neighbouring cells) or 
autocrine (cells stimulating themselves) mechanisms long after the initial PDGF 
secretion. In fact, PDGF-AL is upregulated in vivo during active wound healing 
in response to PDGF-BB treatment (Pierce et al., 1995) and also present in 
cardiac allografts but not normal hearts (Zhao et al., 1995). 
Furthermore, the increase in PDGF-B mRNA induced by some of the cytokines 
(Paper III), may result in increased production of PDGF-BBL, which is 
translocated over the cell membrane, bound to GAGs, and then proteolytically 
cleaved and released as short isoforms (Johnsson et al., 1984). Thus, PDGF-
induced cell proliferation and migration could be sustained by the accumulation 
of long PDGF isoforms bound on GAGs in the arterial wall (Andersson et al., 
1994). Interestingly, the cytokines studied in Paper III can also be stored in the 
cellular matrix (Lôpez-Casillas et al., 1991; Ramsden and Rider, 1992; 
Nagashima et al., 1994; Camejo et al., 1995; Lortat-Jacob et al., 1995) and their 
subsequent release may also result in prolonged effects on hASMC proliferation 
by inducing PDGF expression, leading to intimai hyperplasia long after the 
initial injury. 
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Migration of Early hMDM 
The accumulation of monocytes at the sites of inflammation and endothelial injury is regarded as an early step in atherosclerosis (Holvoet and Collen, 
1997). Since we have shown that early hMDM express both PDGF and PDGF-
Rs, the question arouse whether PDGF could contribute to early hMDM 
migration. Paper IV investigated the potential role of PDGF in this process in 
early hMDM. For migration analyses, PDGF homodimers were used at a 
concentration of 10 nM in the upper and/or the lower compartment in a 
modified Boyden-Chamber. This concentration was chosen since we previously 
found maximal induction of hASMC proliferation between 5-10 nM of 
exogenous PDGF (Paper I). 
Two different migratory responses are seen in PDGF-stimulated cells; either 
stimulated random motility (chemokinesis) or directed migration (Chemotaxis) 
towards increasing concentrations of PDGF (Grotendorst et al., 1982). 
Chemotaxis is of physiological relevance in vivo during wound healing when 
fibroblasts, monocytes, and macrophages migrate to sites of injury. 
Whereas PDGF-induced DNA synthesis and cell proliferation involves 
activation of the Ras proto-oncogene, mitogen-activating protein (MAP) kinase 
kinase, and MAP kinase, the migration of cells is caused by the activation of the 
diacylglycerol-pathway (phosphatidyl-inositol turnover) and an elevation of 
intracellular calcium levels (Fig. 5). This leads to disassembly of actin filaments 
and enables the cell to protrude filopodia (Bornfeldt et al., 1995). Previous 
studies show that activation of the PDGF-Rß leads to both proliferation and 
migration (Bornfeldt et al., 1995). Although PDGF-Ra also transduces a 
mitogenic signal, it mediates migration in a cell-specific manner and stimulation 
of PDGF-Ra, may even inhibit migration (Heldin et al., 1998). Inhibition of the 
migratory response has been attributed to autophosphorylation of certain 
tyrosine residues in the PDGF-Rcx (Yokote et al., 1996). 
Early hMDM exhibited basal motility even in the absence of exogenous PDGF 
(Paper IV). This may be due to auto- or paracrine stimulation from endogenous 
PDGF (Paper II and III) or other factors. Only exogenous PDGF-BBL stimulated 
motility of early hMDM across the filters whereas neither PDGF-AAL, PDGF-
AAS, nor -BBS did (Paper IV). As could be concluded from simple 
checkerboard experiments, this response was rather an increase in random 
motility (chemokinesis) than directed migration (Chemotaxis). IFN-y stimulation 
(known to activate macrophages) upregulated PDGF-Roc which further resulted 
in increased directed migration (Chemotaxis) towards PDGF-AAL. Interestingly, 
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IFN-y induced both PDGF (Paper III) and PDGF-R expression (Paper IV) in 
early hMDM. TGF-ß had only minor effects both on PDGF-R expression and 
on PDGF-induced motility of early hMDM. 
MIGRATION 
Paper IV 
Macrophages 
Fig. 11. Schematic representation of Paper IV. 
These results suggest that PDGF-AAL may be involved in attracting activated 
monocytes to sites of injury. This effect of PDGF-AAL is mediated through an 
upregulation of the PDGF-Ra expression and might suggest an additional role 
of PDGF-AAl in inflammation and tissue repair 
CONCLUDING REMARKS 
The results in this thesis indicate that several cell types occurring in atherosclerotic lesions express PDGF and PDGF-Rs in vitro. This 
expression can be modulated by phenotypic changes and cytokines. Increasing 
levels of PDGF stimulates the proliferation of SMCs and may direct hMDM to 
sites of a growing atherosclerotic lesion. The effect of PDGF is further 
sustained by the occurrence and upregulation of long PDGF isoforms, which 
bind to matrix components. The results suggest that PDGF is a pivotal molecule 
for cell accumulation in atherosclerotic lesions, not only as a mitogen for 
hASMC but also as a chemoattractant for early hMDM. 
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FUTURE PERSPECTIVES 
Increasing knowledge about the expression and function of PDGF isoforms and their receptors may extend the possibility to control cell accumulation 
and migration in the arterial wall. Recently, it was shown that lipid lowering 
reduced levels of PDGF-B in the arterial intima (Aikawa et al., 1998), 
suggesting an indirect strategy for reducing PDGF-induced proliferation. A 
direct approach for reducing PDGF-induced cell accumulation could be to 
intervene with the PDGF/PDGF-R expression or the signalling pathways 
activated by the binding of PDGF to its receptors. 
Since other factors, such as bFGF, have been implicated in SMC proliferation, it 
is interesting to pin-point the exact significance of PDGF for the processes of 
proliferation and migration. This can be elucidated by reducing/inhibiting 
PDGF-R or PDGF expression in the arterial wall through preventing 
transcription of these genes by antisense oligonucleotides. Oligonucleotide-
based gene therapy has been used for treatment of diseases were no effective 
therapy presently exists. Now it is also emerging as a potential strategy for 
treatment of cardiovascular diseases (Morishita et al., 1998). 
The increasing levels of PDGF-Ra after IFN-y stimulation and its potential 
importance for hMDM migration suggests that this regulatory pathway may be 
of potential importance. Increasing the knowledge of the transcription factors 
and signalling pathways responsible for the cytokine-induced PDGF and PDGF-
R expression gives further possibilities to specifically interact with the effects 
exerted by PDGF and its receptors. 
The cytokines in the present thesis have been added one-by-one to the cells. 
However, the in vivo situation is far more complex with a network of cytokines 
interacting with each other. Studies could therefore be extended to investigate 
combinations of different cytokines and their importance for the expression of 
PDGF and PDGF-R in various cell types. 
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